Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2025)
41 slides from Csl's shareholder meeting presentation, Oct 28, 2025
Slide 1: CSL Limited Annual General Meeting 2025
28 October, 2025 Melbourne, Australia CSL Limited Annual General Meeting 2025 CSL Limited (ASX:CSL; USOTC:CSLLY) will hold its 2025 Annual General Meeting at 10.00am AEST today in Melbourne. The following is attached for the information of Investors: • Chair and Chief Executive Officer addresses to
Slide 2: Chair Address at the 2025 CSL Annual General Meeting
Chair Address at the 2025 CSL Annual General Meeting Good morning Ladies and Gentlemen. Thank you for joining us today. There is a quorum present, and I am delighted to open the meeting. To my right: • Closest to me is Ms Fiona Mead, our Company Secretary, who you’ve already heard from; • Dr Megan C
Slide 3: Chair address: FY25 results and simplification of the business
I’ll then hand over to CSL’s Chief Executive Officer and Managing Director Dr Paul McKenzie, who will provide a review of the business and our performance in Financial Year 2025, progress against our strategy and outlook for Financial Year 2026. We’ll then move onto the procedural matters of today’s
Slide 4: Charting a path forward
We are charting a path forward—one that builds on our strengths, our history and our strong culture but also focuses on market challenges. Specifically: • We are implementing an improved commercially driven operating model to bring decisive speed and focus to how we run the business and drive demand
Slide 5: CEO and Managing Director Address at the 2025 CSL AGM
CEO and Managing Director Address at the 2025 CSL Annual General Meeting Thank you, Brian. Good morning to everyone in the room and online. It is a pleasure to be here with you today to discuss the outlook for your company and our progress against our strategy. These meetings are an important remind
Slide 6: VarmX partnership and first-half impacts
partnership with VarmX, we will develop a first-in-class treatment for patients on FXa inhibitors who require urgent surgery or experience severe bleeding. This collaboration not only addresses a significant unmet medical need but also strengthens our innovation pipeline and our ambition to deliver en
Slide 7: Taking action to deliver growth
My focus as CEO—and that of your management team—is taking the right action to deliver growth. The changes we are putting in place will enhance the resiliency of the overall business. Brian is right. These are bold strategic steps to realise the company’s full potential that have been put in place f
Slide 8: Operational excellence and executive appointments
Our operational excellence will drive reliable supply expansion and cost optimisation. Our teams are laser focused on the end-to-end fundamentals of plasma economics, further reducing collection and processing costs per litre. We continue to innovate in our centres through the now completed roll out
Slide 9: Long-term outlook and closing remarks
I share Brian’s confidence in CSL’s long-term outlook, as well as his commitment to accelerating progress. A big part of what makes this company unique is our history and our people – more than 29,000 colleagues worldwide impacting the lives of millions. I never tire of hearing stories of how our peo
Slide 10: Continuation of the Chair Address: Seqirus demerger
Continuation of the Chair Address at the 2025 CSL Annual General Meeting Thanks Paul. I want to reiterate the strength of CSL Behring, growth in IG and our new products. I would like to address one of the challenges Paul mentioned—specifically, the US vaccine market. In August, we communicated a well
Slide 11: Board updates and new directors
Tackling these various initiatives requires having the right people at the Board level, with the right mix of skills and experience to guide our strategy and lead our operations in an increasingly complex global environment. That means not only the traditional essentials like risk management, scient
Slide 12: Retiring directors
And finally, I’d like to take a moment to acknowledge two long-serving members of our Board who will be retiring at the conclusion of today’s AGM — Ms Marie McDonald and Dr Megan Clark. Marie joined the CSL Board in August 2013 and has brought a wealth of experience across law, and medical research.
Slide 13: Remuneration report vote and Tullamarine facility
This year it is clear from the votes received that many of our shareholders have voted against the remuneration report. This will trigger a spill resolution which we will put to the meeting. We understand the importance of finding the right balance between offering executive remuneration packages th
Slide 14: Welcome to CSL's 2025 Annual General Meeting
Welcome to CSL’s Driven by Our Promise 2025 Annual General Meeting Please ensure your mobile is on silent mode
Slide 15: Welcome to CSL's 2025 AGM: Fiona Mead
Welcome to CSL’s 2025 AGM Fiona Mead Company Secretary 2
Slide 16: Online Text Questions
Online Text Questions • Select the messaging icon • Type your question in the box • Press the send button • Select ‘My Messages’ to view your submitted messages along with any written responses
Slide 17: Online Audio Questions
Online Audio Questions • Click ‘Request to Speak’ • Enter the topic of your question • Click ‘Submit Request’ • Click ‘Join Queue’ and follow the audio prompts
Slide 18: Online difficulties
Online difficulties If you experience any difficulty with your participation via the online platform, please call +61 2 8075 0100 5
Slide 19: In Room Voting
In Room Voting • Shareholders (and proxies who have been given discretion on how to vote) should tick FOR, AGAINST, or ABSTAIN for each resolution. • Please sign your completed voting card and place it in one of the Polling Boxes POWERED BY
Slide 20: Online attendees – Online voting
Online attendees – Online voting • Select the voting tab • Select your voting preference for each resolution • Your selected option will change colour • You can change your vote until the poll is closed 7
Slide 21: Legal Notice
Legal Notice IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) The forward-looking statements are based on CSL's good faith assumptions as to the and its related bodies corporate (together, CSL) and CSL's activities as at the date of t
Slide 22: Address from the Chair
Address from the Chair Brian McNamee AO Chair and Independent Non-Executive Director 9
Slide 23: Board of Directors and Company Secretary
Board of Directors and Company Secretary Paul McKenzie Megan Clark AC Andrew Cuthbertson AO Carolyn Hewson AO Samantha Lewis Marie McDonald Managing Director Non-executive Director Non-executive Director Non-executive Director Non-executive Director Non-executive Director Elaine Sorg Alison Watkins
Slide 24: CSL Limited listed on the ASX
Brian McNamee AO CSL Limited listed on the ASX 3 June 1994 11
Slide 25: Slide 25
Slide 26: Strategic transformation to deliver value
Reduce non-clinical Strategic transformation to deliver value fixed cost in R&D Annual pre-tax savings of A refocused CSL will… Operating model complexity >$500m by the end of FY28* Direct savings to accelerate has increased clinical pipeline and with growth, priority programs against a volatile mac
Slide 27: Performance in FY25
Performance in FY25* Revenue +5% $15,558m NPATA* +14% NPAT* +17% Leverage 1.8x FCF* +58% Revenue CSL Behring +6% Growth* +2% Dividend* +12% CSL Seqirus CSL Vifor +8% *For further information, and for all definitions, please see CSL’s 2025 Full Year Results Investor Presentation on csl.com 14
Slide 28: FY26 Updated Outlook
FY26 Updated Outlook Majority of business tracking to plan FY26 Updated Outlook Revenue Growth • Ig fundamentals strong ~2-3% @ CC • ANDEMBRY® launch ahead of plan • VarmX partnership NPATA Growth (excl. restructuring cost) • Transformation program progressing well ~4-7% @ CC1 CSL Seqirus FY27 and F
Slide 29: Strategic transformation to deliver value
Reduce non-clinical Strategic transformation to deliver value fixed cost in R&D Annual pre-tax savings of A refocused CSL will… Operating model complexity >$500m by the end of FY28* Direct savings to accelerate has increased clinical pipeline and with growth, priority programs against a volatile mac
Slide 30: 17
17
Slide 31: Patients Emma & Izzi
Patients Emma & Izzi 18
Slide 32: 19
19
Slide 33: New Appointments: Mary Oates, Chief Operating Officer
New Appointments Mary Oates Chief Operating Officer 20
Slide 34: New Appointments: Andy Schmeltz, Chief Commercial Officer
New Appointments Andy Schmeltz Chief Commercial Officer 21
Slide 35: New Appointments: Ken Lim, Chief Financial Officer
New Appointments Ken Lim Chief Financial Officer 22
Slide 36: 23
23 23
Slide 37: Address from the Chair
Address from the Chair Brian McNamee AO Chair and Independent Non-Executive Director 24
Slide 38: CSL Seqirus demerger
CSL Seqirus demerger • Since announcement of demerger in Strategic rationale for separation August 2025, US influenza vaccination rates remains strong have declined at a greater rate than expected World-class vaccines business with the autonomy, accountability and agility to drive growth • Demerger
Slide 39: Tullamarine Australia
Tullamarine Australia 26
Slide 40: 27
27
Slide 41: Thank you
CSL’s 2025 Thank you Annual General Meeting